Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

References

• Messmer BT, Messmer D, Allen SL . In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755–764.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008;26:4497–4503.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Küppers R, . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37–50.
   PubMed Web of Science ®Google Scholar
• Zenz T, Mertens D, Stilgenbauer S. Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. Haematologica 2010;95:1441–1443.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Karlsson K, . Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004;104:2879–2885.
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, . Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007;109:259–270.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, . Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262–2264.
   PubMed Web of Science ®Google Scholar
• Ghia EM, Jain S, , Widhopf GF 2nd. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008;111:5101–5108.
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, Bron D, . Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91:2387–2396.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, . Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Kitada S, Leoni LM, . Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795–1801.
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Jones D, Ganeshaguru K, . Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97–103.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, . Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Seiffert M, Stilgenbauer S, Döhner H, . Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007;21:1977–1983.
   PubMed Web of Science ®Google Scholar
• Seiffert M, Schulz A, Ohl S, . Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010;116:4223–4230.
   PubMed Web of Science ®Google Scholar
• Ghia P, Circosta P, Scielzo C, . Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005;294:135–145.
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, . Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4 +, CD40L + T cells by producing CCL22. Eur J Immunol 2002;32:1403–1413.
   PubMed Web of Science ®Google Scholar
• Burger JA, Quiroga MP, Hartmann E, . High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009;113:3050–3058.
   PubMed Web of Science ®Google Scholar
• Mikaelsson E, Danesh-Manesh AH, Lüppert A, . Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 2005;105:4828–4835.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Secreto CR, Knox TR, . Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010;115:1755–1764.
   PubMed Web of Science ®Google Scholar
• Woessner S, Asensio A, Florensa L, . Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1994;13:457–461.
   PubMed Web of Science ®Google Scholar
• Hartmann TN, Grabovsky V, Wang W, . Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009;69:3121–3130.
   PubMed Web of Science ®Google Scholar
• Gu B, Dao L-P, Wiley J. Impaired transendothelial migration of B-CLL lymphocytes: a defect linked to low L-selectin expression. Leuk Lymphoma 2001;42:5–12.
   PubMed Web of Science ®Google Scholar
• Till KJ, Zuzel M, Cawley JC. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 1999;59:4419–4426.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Mertens D, Buhler A, . The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2009;23:519–527.
   PubMed Web of Science ®Google Scholar
• Buggins AGS, Levi A, Gohil S, . Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011;154:216–222.
   PubMed Web of Science ®Google Scholar
• Redondo-Muñoz J, Ugarte-Berzal E, García-Marco J, . Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008;112:169–178.
   PubMed Web of Science ®Google Scholar
• Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, . Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010;17:160–172.
   PubMed Web of Science ®Google Scholar
• de Martel C, Franceschi S. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009;70: 183–194.
   PubMed Web of Science ®Google Scholar
• Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447–458.
   PubMed Web of Science ®Google Scholar
• Soucek L, Lawlor ER, Soto D, . Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211–1218.
   PubMed Web of Science ®Google Scholar
• Sodir NM, Swigart LB, Karnezis AN, . Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011;25:907–916.
   PubMed Web of Science ®Google Scholar
• Bhattacharya N, Diener S, Idler IS, . Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14(+) cells from peripheral blood. Leukemia 2011;25:722–726.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Ding W, Nowakowski GS, Knox TR, . Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009;147:471–483.
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky GA, . Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625–1638.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, . CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003;102:2146–2155.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kato RM, Lansigan F, . Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci USA 2000;97:5504–5509.
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, . Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100:4609–4614.
   PubMed Web of Science ®Google Scholar
• Contri A, Brunati AM, Trentin L, . Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005;115:369–378.
   PubMed Web of Science ®Google Scholar
• Semichon M, Merle-Beral H, Lang V, . Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells. Leukemia 1997;11:1921–1928.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Gordon AL, Hertlein E, . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Quiroga MP, Balakrishnan K, Kurtova AV, . B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029–1037.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, . Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Amrein PC, Attar EC, Takvorian T, . Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2977–2986.
   PubMed Web of Science ®Google Scholar
• Schattner EJ. CD40 ligand in CLL pathogenesis and therapy. Leuk Lymphoma 2000;37:461–472.
   PubMed Web of Science ®Google Scholar
• Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol 2010;20:424–430.
   PubMed Web of Science ®Google Scholar
• Muzio M, Bertilaccio MTS, Simonetti G, . The role of Toll-like receptors in chronic B cell malignancies. Leuk Lymphoma 2009;50:1573–1580.
   PubMed Web of Science ®Google Scholar
• Hewamana S, Alghazal S, Lin TT, . The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681–4689.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995–1004.
   PubMed Web of Science ®Google Scholar
• Romano MF, Lamberti A, Tassone P, . Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92:990–995.
   PubMed Web of Science ®Google Scholar
• Kater AP, Evers LM, Remmerswaal EBM, . CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404–415.
   PubMed Web of Science ®Google Scholar
• Pepper C, Lin TT, Pratt G, . Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807–3817.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, . Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Perez-Galan P, Liu D, . The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
   PubMed Web of Science ®Google Scholar
• Schulz A, Toedt G, Zenz T, . Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011;96:408–416.
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio M, . Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:507–516.
   PubMed Web of Science ®Google Scholar
• Porakishvili N, Kulikova N, Jewell AP, . Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005;131:313–319.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Mühlenhoff L, Blackwell SE, . B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490–1499.
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, . The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2006;21:110–120.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, . Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2005;20:286–295.
   Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, . Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, . A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2009;24:222–226.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kelly JL, Neuberg D, . Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282–291.
   PubMed Web of Science ®Google Scholar
• Geller M, Cooley S, Argenta P, . Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother 2010;59:1877–1884.
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Unkeless JC, . TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008;27:218–224.
   PubMed Web of Science ®Google Scholar
• Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008;57:1271–1278.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Mertens D, Buhler A, . The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 2008;23:519–527.
   PubMed Web of Science ®Google Scholar
• Vlad A, Deglesne PA, Letestu R, . Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009;69:6387–6395.
   PubMed Web of Science ®Google Scholar
• Sivina M, Hartmann E, Kipps TJ, . CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011;117:1662–1669.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481–488.
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Zenz T, Vollmer D, Trbusek M, . TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072–2079.
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, . Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703–2708.
   PubMed Web of Science ®Google Scholar
• Zenz T, Frohling S, Mertens D, . Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010;23:71–84.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, . Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448–5457.
   PubMed Web of Science ®Google Scholar
• Dickinson JD, Gilmore J, Iqbal J, . 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006;47:231–244.
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher MR, Kofler DM, . Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006;107:742–751.
   PubMed Web of Science ®Google Scholar
• Tam CS, Otero-Palacios J, Abruzzo LV, . Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 2008;141:36–40.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, . Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944–13949.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, . Identification of novel genes coding for small expressed RNAs. Science 2001;294:853–858.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Greenman CD, Fu B, . Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27–40.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Baldoni S, Rosati E, . A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146: 689–91.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• Sportoletti P, Baldoni S, Cavalli L, . NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 2010;151:404–406.
   PubMed Web of Science ®Google Scholar
• Fabbri G, Rasi S, Rossi D, . Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:1389–1401.
   PubMed Web of Science ®Google Scholar
• Kawagoe T, Sato S, Matsushita K, . Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008;9:684–691.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, . Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, . Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438–2447.
   PubMed Web of Science ®Google Scholar
• Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009:602–609.
   Google Scholar
• Dreger P, Corradini P, Kimby E, . Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007;21:12–17.
   PubMed Web of Science ®Google Scholar
• Austen B, Powell JE, Alvi A, . Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005;106:3175–3182.
   PubMed Web of Science ®Google Scholar
• Schaffner C, Stilgenbauer S, Rappold GA, . Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748–753.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Weber P, Stewart G, . Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26–29.
   PubMed Web of Science ®Google Scholar